Why Intercept Pharmaceuticals (ICPT) Stock Is Spiking In Pre-Market Trading Today

NEW YORK (TheStreet) -- Intercept Pharmaceuticals  (ICPT) shares are up 45.88% to $346 in pre-market trading on Tuesday after releasing positive data on its fatty liver drug treatment, obeticholic acid (OCA).

The new data shows OCA reduced the signs and symptoms of non-alcoholic steatohepatitis (NASH) compared to placebo. NASH is a disease of the liver that affects 2% to 5% of Americans and has no current treatment.

Intercept plans to start a phase III study of OCA in NASH next year.

Highlights from the analysis by TheStreet Ratings Team follows:

ICPT Chart ICPT data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE

More from Markets

Asia Markets Fall on Latest Tariff Threats From Trump

Asia Markets Fall on Latest Tariff Threats From Trump

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Dow Drops Over 100 Points on Trade War Worries

Dow Drops Over 100 Points on Trade War Worries